Site maintenance Wednesday, November 13th, 2024. Please note that access to some content and account information will be unavailable on this date.
Skip to main content
Full access
Letter to the Editor
Published Online: 1 December 2003

Lethal Gastroenteritis Associated With Clozapine and Loperamide

To the Editor: Clozapine is an effective and widely used antipsychotic medicine in the United States and elsewhere. Furthermore, loperamide is a common antimotility drug, usually considered quite safe. Here we describe a case of fatal gastroenteritis associated with the simultaneous use of clozapine and loperamide.
In Niuvanniemi State Mental Hospital in Kuopio, Finland, an unexpected, extensive epidemic of intestinal disease broke out; within 24 hours 85 patients and 26 employees suffered diarrhea, abdominal cramps, and vomiting. There were no local neurological symptoms or fever. Most cases were mild, but six people, all patients, were hospitalized. One of these patients later died, despite previous physical good health and an age of 36. This man died on the operating table after about 16 hours of symptoms. The autopsy revealed toxic megacolon as the immediate cause of death and acute gastroenteritis as the basic cause. He had received 500 mg of clozapine daily and, after the diarrhea, 6 mg of loperamide. He received no other drugs.
Standard analyses of all known food sources as well as samples of feces and vomitus revealed no significant causes of the epidemic. This process led to preparation of a fresh batch of vanilla sauce like that served before the epidemic.
An epidemiological questionnaire, the foodstuff analyses, temperatures of the replicated vanilla sauce, and the microbiological results all confirmed the vanilla sauce as the cause. The pathogen was determined to be either Bacillus licheniformis alone or concurrent with B. cereus. Toxin-producing strains of B. licheniformis have been previously reported (1) and, together with B. cereus (2), have been known to cause food poisoning.
The most seriously affected people in the hospital were patients, not personnel. Furthermore, the diarrhea was generally followed by some deceleration of intestinal function and abdominal distension. The issue of pharmaceutical influences surfaced. Some patients had received loperamide, an antimotility drug, for relief of symptoms. The deceased patient received loperamide and clozapine. According to the literature, loperamide should not produce pharmacokinetic interactions with clozapine or other antipsychotics, which are also antimotility agents. Pharmacodynamically, however, this intestinal deceleration was relevant. We performed a search using PubMed, available through the National Center for Biotechnology Information Entrez retrieval system (3), and also requested reports from the databases of the Finnish National Agency for Medicines, Novartis (clozapine), and Orion Pharma Finland (loperamide). There were no reports of similar cases specifically involving psychiatric patients. However, antimotility agents have previously been identified in fatal Campylobacter jejuni infections (4). It can be reasonably concluded that the simultaneous use of clozapine, or other antipsychotics with anticholinergic properties causing constipation, and antimotility drugs may expose patients to serious intestinal infections. The results may not be as serious when loperamide is combined with antipsychotics lacking these properties. This should be considered when treating gastroenteritis in psychiatric patients.

References

1.
Mikkola R, Kolari M, Andersson MA, Helin J, Salkinoja-Salonen MS: Toxic lactonic lipopeptide from food poisoning isolates of Bacillus licheniformis. Eur J Biochem 2000; 267:4068–4074
2.
Jephcott AE, Barton BW, Gilbert RJ, Shearer CW: An unusual outbreak of food-poisoning associated with meals-on-wheels. Lancet 1977; 2:129–130
3.
National Center for Biotechnology Information Databases. Bethesda, Md, National Institutes of Health, National Library of Medicine. http://www.ncbi.nlm.nih.gov/Database/index.html
4.
Smith GS, Blaser MJ: Fatalities associated with Campylobacter jejuni infections. JAMA 1985; 253:2873–2875

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 2242 - 2243
PubMed: 14638602

History

Published online: 1 December 2003
Published in print: December 2003

Authors

Details

MARKKU ERONEN, M.D., Ph.D.
Vaasa and Kuopio, Finland
HANNA PUTKONEN, M.D., Ph.D.
Vaasa, Finland
TERO HALLIKAINEN, M.D.
Kuopio, Finland
HEIKKI VARTIAINEN, M.D., Ph.D.
Helsinki, Finland

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share